New onset diabetes after transplantation (NODM) is a multifactorial condition with genetic and environmental components that affects many organ transplant recipients. NODM develops in 10-30% of liver transplant recipients (Driscoll, 2006) who must now cope with this new health care problem. Studies have identified some common environmental risk factors including age, ethnicity, and immunosuppression (Driscoll, 2007). Hepatitis C (HCV), a leading indication for liver transplantation, is one of the most significant risk factors for developing NODM (Driscoll, 2007). Fewer studies have examined genetic components of NODM. However, differences in gene expression in the blood of liver transplant recipients with and without NODM have recently been identified (Driscoll, 2006). Data on gene expression or genotype differences would contribute to a better understanding of the biologic processes associated with the development of NODM. Improved understanding of the pathophysiologic process associated with NODM may enhance early intervention, treatment, and ultimately prevention strategies.